In this first limb of the PROACT , patients with elevated risk factors for thromboembolism were randomized at 33 US centers to receive lower dose warfarin ( test international normalized ratio [ INR ] , 1.5-2 .0 ) or continue standard warfarin ( control INR , 2.0-3 .0 ) , 3 months after mechanical aortic valve replacement .